NASDAQ$AZTA
Azenta Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported preliminary results for the second quarter, driven by robust customer demand and strong operational execution.
Azenta Life Sciences reported preliminary financial results for Q2 2022, showing a 12% increase in revenue from continuing operations compared to the previous year. Revenue reached $146 million, driven by growth in both Life Sciences Products and Services. Diluted EPS from continuing operations was ($0.02) per share, while non-GAAP diluted EPS was $0.12.
- Revenue from continuing operations was $146 million, a 12% increase year-over-year and a 4% sequential increase.
- Life Sciences Products revenue grew 2% year-over-year, driven by automated cryogenic freezers.
- Life Sciences Services revenue increased 19% year-over-year, with growth in Sample Repository Solutions and Genomics Services.
- Diluted EPS from continuing operations was ($0.02) per share, while total diluted EPS was $28.15, including discontinued operations.
Headline financials
Revenue & EPS history
Azenta · Revenue · Quarterly
$146M
Forward guidance
The Company announced revenue and earnings guidance for continuing operations for the third quarter of fiscal 2022. Revenue is expected to be in the range of $140 million to $150 million and non-GAAP diluted earnings per share for the third fiscal quarter is expected to be in the range of $0.09 to $0.17. GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.03) to $0.05.
Tailwinds
- Revenue is expected to be in the range of $140 million to $150 million.
- Non-GAAP diluted earnings per share for the third fiscal quarter is expected to be in the range of $0.09 to $0.17.
Headwinds
- GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.03) to $0.05.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.6%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+0.4%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+22.4%
Q4 2025
Best reaction
-23.4%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -21.6% | -21.0% | -6.1% | |
| Q1 2026 | -23.4% | -19.3% | -34.2% | |
| Q4 2025 | +22.4% | +20.9% | +14.8% | |
| Q2 2025 | -0.7% | +11.3% | +13.1% | |
| Q1 2025 | +3.4% | -8.6% | -16.0% | |
| Q4 2024 | -2.9% | -9.4% | +0.2% | |
| Q3 2024 | -4.9% | -1.1% | -15.4% | |
| Q2 2024 | -4.8% | -6.9% | -2.1% | |
| Q1 2024 | -4.0% | -1.2% | -2.0% | |
| Q4 2023 | +14.6% | +16.1% | +27.2% | |
| Q3 2023 | +21.8% | +18.4% | +11.0% | |
| Q2 2023 | -19.8% | -11.1% | +0.0% | |
| Q1 2023 | -20.8% | -22.2% | -29.7% | |
| Q4 2022 | +15.8% | +17.5% | +25.8% | |
| Q3 2022 | -10.3% | -8.7% | -23.8% | |
| Q2 2022 | -4.0% | +5.6% | +8.9% | |
| Q1 2022 | +5.6% | -3.1% | -7.0% | |
| Q4 2021 | -7.6% | -7.1% | -16.7% | |
| Q3 2021 | -4.0% | -4.0% | -3.5% | |
| Q2 2021 | -7.3% | -7.1% | -2.9% | |
| Q1 2021 | -2.8% | -0.3% | -4.2% | |
| Q4 2020 | +9.7% | +12.8% | +19.9% | |
| Q3 2020 | +17.8% | +21.2% | +13.2% | |
| Q2 2020 | -15.4% | -12.3% | -3.9% | |
| Q1 2020 | -1.4% | +6.7% | -15.1% | |
| Q4 2019 | +7.8% | +5.5% | -7.7% | |
| Q3 2019 | -15.7% | -17.0% | -14.1% | |
| Q2 2019 | +18.5% | +23.4% | +15.6% | |
| Q1 2019 | +0.9% | -5.3% | -0.4% | |
| Q4 2018 | -11.6% | -10.9% | -13.6% | |
| Q3 2018 | -7.2% | -5.8% | +22.3% | |
| Q2 2018 | +8.4% | +12.5% | +31.4% | |
| Q1 2018 | -3.4% | -9.5% | -2.4% | |
| Q4 2017 | -23.3% | -21.2% | -28.8% | |
| Q3 2017 | -8.1% | +0.9% | +6.6% | |
| Q2 2017 | +6.0% | +9.4% | +16.3% | |
| Q1 2017 | +16.9% | +20.6% | +20.0% | |
| Q4 2016 | +7.7% | +11.7% | +20.1% | |
| Q3 2016 | -3.3% | -5.4% | -1.7% | |
| Q2 2016 | -7.3% | — | — | |
| Q1 2016 | -1.7% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | +11.2% | — | — | |
| Q2 2015 | -0.5% | — | — | |
| Q1 2015 | -5.1% | — | — | |
| Q4 2014 | +6.0% | — | — | |
| Q3 2014 | +2.7% | — | — | |
| Q2 2014 | +1.1% | — | — | |
| Q1 2014 | -1.3% | — | — | |
| Q4 2013 | +2.9% | — | — | |
| Q3 2013 | -4.0% | — | — | |
| Q2 2013 | +2.7% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +1.3% | — | — | |
| Q3 2012 | -13.8% | — | — | |
| Q2 2012 | -1.1% | — | — | |
| Q1 2011 | +7.2% | — | — | |
| Q1 2012 | +7.2% | — | — | |
| Q4 2009 | +2.8% | — | — | |
| Q2 2011 | +2.8% | — | — | |
| Q4 2011 | +2.8% | — | — | |
| Q4 2010 | -0.1% | — | — | |
| Q3 2010 | -0.1% | — | — | |
| Q3 2011 | -0.1% | — | — | |
| Q2 2010 | -6.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro